Introduction
Inflammation and atherosclerosis
The role of IKKβ/NF‑κB in the development of atherosclerosis
The role of IKKβ in key cell types and the influence on atherosclerosis
Endothelial cells IKKβ and atherosclerosis
Macrophages IKKβ and atherosclerosis
Vascular smooth muscle cells IKKβ and atherosclerosis
Anti-inflammatory therapy targeting IKKβ in atherosclerosis
Natural product-based derivatives
Natural extracts
Synthetic drugs
Other drugs
Therapeutic potential and future considerations
Classification/Name | major ingredient | Drug Class | Drug Source | Effective Dose of Drug | Animal/Cell Model Induction | Effect | Target | Pathway | Ref | |
---|---|---|---|---|---|---|---|---|---|---|
Natural products-based derivatives | ||||||||||
Vinpocetine | Vinpocetine | Vincamine alkaloid | Vinca minor | 5 mg/kg (i.p.) | high cholesterol diet (16.6% fat, 10.6% sucrose and 1.3% cholesterol) for 12 weeks + apoE−/− mice-induced atherosclerosis model | anti-inflammatory, anti-oxidant stress, inhibit monocyte adhesion to ECs | TNF-α, IL-6, MCP-1, MCP-1, MMP-2, MMP-9↓ | p-Akt, p-IKKα, p-IKKβ, p-IκBα ↓ | Akt/NF-κB | [80] |
30, 50 µM | 20 μg/ml ox-LDL + PMA-induced macrophages for 12 h | |||||||||
20 μg/ml ox-LDL + (HUVECs + THP-1 cells) to induce monocyte-endothelial cell adhesion | ||||||||||
Metformin | guanidine | hypoglycemic agents | Galega officinalis | 200 mg/kg/day (p.o.) | atherogenic diet (0.8% cholesterol and 3% soybean oil) for 10 weeks + new zealand white rabbits to induce atherosclerosis model | anti-inflammatory, inhibit monocyte adhesion to ECs | MCP-1, CRP, TNF-α, IL-6, IL-4, IL-10, IL-8, IL-1, VCAM-1, ICAM-1, LOX-1 ↓ | p65 ↓, IκBα ↑ | - | [86] |
100, 200, 300 µM/ml | 10 ng/ml TNF-α + rabbit endothelial cells + rabbit monocytes | |||||||||
100, 500,1000 µM | 10 ng/ml TNF-α + HUVECs-induced inflammation | anti-inflammatory | IL-6 ↓ | P-IKKα/β↓, IκBα, P-AMPK, αAMPK ↑ | PI3K/AMPK/IKKα/β | [88] | ||||
10−3 mol/L | (10−4 mmol/L Insulin + 30 mM glucose + 1 µM dexamethasone) + HUVECs-induced Insulin resistance of endothelial cells model | enhance endothelial function | NO, eNOS, ET-1 ↑ | - | - | [84] | ||||
Naringin | Naringin | flavonoid | grape, citrus species, fractus aurantii | 50, 100, 200 μg/ml | 10 ng/ml TNF-α stuimilated-HUVECs + THP-1- induced inflammation and monocyte adhesion | anti-inflammatory, inhibit monocyte adhesion to ECs | ICAM-1,VCAM-1, MCP-1, E-selectin, RANTES↓ | p-p65, p-IκBα, p-IKKα/β ↓, IκBα ↑ | IKK/NF-κB | [92] |
Emodin | Emodin | anthraquonoid compound | dried root of Rhei Rizoma | 10 µM | 100 ng/ml Light + monocyte-like cell line (THP-1) to induce monocytes migration | anti-inflammatory, inhibit migration | CCR1, CCR2, ICAM-1, IL-8, MCP-1, TNF-α, IL-6 ↓ | p38, p-p38, p-IκBα | p38/NF-κB | [94] |
10 µM | 10 ng/ml TNF-α inducing rat aortic VSMCs migration | anti-inflammatory | MMP-2, MMP-9, MCP-1, IL-1β, IL-6, ICAM-1, VCAM-1↓ | - | NF-κB pathway | [95] | ||||
Green tea polyphenols | Epigallocatechin gallate | polyphenols | green tea | 0.1, 0.2, 0.4 mg/ml | 50 mg/ml ox-LDL + HUVECs-induced inflammation model | anti-inflammatory, improve endothelial dysfunction | TNF-α↓ | p65↓ | IKK/NF-κB | [99] |
Stybenpropol A | Stybenpropol A | phenylpropane derivative | Benzoinum | 50, 200 μmol/ L | 12.5 ng/ml TNF-α + HUVECs-induced inflammation | anti-inflammatory, anti-apoptotic | sVCAM-1, sICAM-1, IL-1β, IL-8, Caspase-9, Bax↓, Bcl-2 ↑ | IKKβ, IκBα ↑ | IKK/NF-κB | [100] |
Methyl-β-cyclodextrin | Methyl-β-cyclodextrin | cyclic oligosaccharide | starch hydrolysis enzymatic | 5 nM | (1 μg/ml LPS / 50 μg/ml ox-LDL) + (HUVECs + THP-1)-induced monocyte-endothelial adhesion | inhibit monocyte adhesion to ECs | ICAM-1, VCAM-1↓ | p-p65, p65, IKK, Akt↓, IκB, p-Akt↑ | LPS/IKK/NF-κB, oxLDL/Akt/NF-κB | [51] |
Natural extracts | ||||||||||
Tanshinone IIA | Tanshinone IIA | Diterpene | Salvia miltiorrhiza bunge | 90, 30 10 mg/kg/day (p.o.) | high-fat diet (fat: 21% (wt/wt), cholesterol: 0.15% (wt/wt)) for 13 weeks + ApoE−/− mice-induced atherosclerosis model | anti-inflammatory | MC-1, TNF-α ↓ | TLR4, MyD88, NF-κB ↓ | TLR4/MyD88/NF-κB | [104] |
5, 10, 20 µg/ml | 10 ng/ml TNF-α + (HUVECs + THP-1)-induced inflammation | anti-inflammatory | ICAM-1,VCAM-1, TNF-α, E-selectin ↓ | IKKα/β, p-IKKα/β, p65, p-IκBα, p-p65↓, IκBα↑ | IKK/NF-κB | [105] | ||||
Quercetin | Quercetin | Flavonoid subclass | fruits and vegetables | 0.1%, w/w in diet | human CRP transgenic mice + IL-1β 100 L/mouse (i.p.); ApoE*3 leiden transgenic mice + high cholesterol diet (15% (w/w) cacao butter, 1% (w/w) palm oil, 40.5% sucrose, 20% acid casein, 10% corn starch and 6.2% cellulose, supplemented with or without 1% cholesterol (all w/w) for 15 weeeks-induced AS model | anti-inflammatory, anti-proliferation | CRP, SAA, E-selectin, VCAM-1 ↓ | p65 | - | [109] |
10, 30 µmol/L | 0.2 mmol/L H2O2/10 U/ml TNF-α/IL-1β 5 ng/ml- stimulated HUVECs/human HuH7 hepatoma cells | |||||||||
Myricetin | myricetin | flavonoid | fruits, vegetables, medicinal herbs | - | TNF-α + ECV304 cells-induced inflammation | inhibit monocyte adhesion to ECs | - | IKK, p65, IκB ↓ | IKK/NF-κB/IκB | [115] |
10 µgl/ml | 10 ng/ ml LPS + dendritic cells-induced cells inflammation model | anti-inflammatory | TNF-α, IL-6, IL-12p70 ↓ | P65, p-IKKα/β, p-IκBα ↓, IκBα ↑ | IKK/NF-κB | [178] | ||||
Clematichinenoside | Clematichinenoside | triterpene saponin | Clematis chinensis osbeck root | 1, 3, 10 µM | 10 ng/ml TNF-α + HUVECs-induced inflammation | anti-oxidant stress, suppress monocyte- HUVECs adhesion | ICAM-1,VCAM-1, ROS, O2(∙-), H2O2, NOX4, p47↓ | p-IκBα, IKKβ, p65↓, IκBα ↑ | IKK/NF-κB | [118] |
Andrographolide | Andrographolide | diterpene lactone | leaves | 10 μM | 1 ng/ml TNF-α + EA.hy926 cells -induced inflammation | anti-inflammatory | ICAM-1 ↓ | p-IKKβ/IKKβ, p-IκBα, p-IKKα/IKKα, p65↓, IκBα ↑ | IKK/NF-κB | [179] |
Avenanthramide-c | CH3-Avenanthramide-c | polyphenol | Avena sativa | 50, 100 μM | 100 ng/ml TNF-α + human aortic SMCs to induce proliferation and migration | anti-inflammatory, anti-proliferation | MMP-2, MMP-9, TNF-α, IL-1β, IL-6 ↓ | p65, p-IκB, p-ERK1/2, p-JNK, p-p38↓, IκB ↑ | MAPK/NF- κB | [123] |
20, 40, 100 μM | 5 ng/ml hrIL-1β + HAECs / 20 ng/ml TNF-α + HUVECs-induced inflammation | anti-inflammatory | IL-6, IL-8, MCP-1↓ | p65, p-IKKα, p-IKKβ, p-IκB↓, IκBα↑ | IKK/NF-κB | [124] | ||||
Digitoxin | digitoxin | steroid glycoside | Digitalis | 3, 10, 30 nmol/l | 10 ng/ml IL-1β + HUVECs-induced inflammation | anti-inflammatory | MCP-1, Caspase-3, eNOS↓ | p65, p-TAK1, p-IKK, p-IκBα ↓, IκBα↑ | TAK-1/IKK/NF-κB | [126] |
Kansuinine A | Kansuinine A | Terpenoid | Euphorbia kansui L | 20, 60 μg/ kg (i.p.) | A high fat-diet + ApoE−/− mice + -induced atherosclerosis model | anti-oxidant stress, anti-apoptotic, anti-inflammatory | ROS, GPx, MDA, Bax, Bcl-2, CC3 ↓ | p-p65, p65, p-IKKβ, IKKβ, p-IκBα↓, IκBα ↑ | IKKβ/IκBα/NF-κB | [128] |
0.1, 0.3, 1.0 μM | 200 μM H2O2 + HAECs-induced endothelial injury | |||||||||
Honokiol | Honokiol | pleiotropic lignan | Magnolia grandiflora | 10 μM | 0.5 mM Palmitic acid (PA) + HUVECs-induced endothelial cell injury model | anti-inflammatory | IL-6, IL-8, MCP-1, NO, iNOS, eNOS ↓ | p-IKKβ, p-IκB, p50, p65↓ | IKK/IκB/NF-κB | [131] |
Longxuetongluo capsule | Dragon's Blood | totaenolic extract | Croton, Dracaen, Daemonorops, Pterocarpus | 100, 200, and 300 mg/kg/d (p.o.) | A high-fat diet (0.2% cholesterol,15% fat added) for 7 weeks + ApoE−/− mice-induced atherosclerosis model | anti-inflammatory, inhibit the adhesion of monocytes to HUVECs | eNOS ↑, VCAM-1, MCP-1, COX-2 ↓ | p-ErK/ErK, p-IKKα/β, p-IκBα, IKKβ, IKKα, p-p38/p38↓, IκBα ↑ | p38/IKK/IκB/NF-κB | [180] |
20, 40 µg/ml | 20 µg/ml ox-LDL + (HUVECs + THP-1)-induced inflammation | |||||||||
Pulvones A/C | pulvones A/C | isoflavonoids | Millettia pulchra | 3, 10 µM | 1 µg/ml LPS + RAW264.7 macrophage cells to induce inflammation | anti-inflammatory | iNOS, COX-2, IL-6, IL-1β↓ | p65, IKK, p-IκBα↓, IκBα↑ | IKKβ/NF-κB | [133] |
Acetyl-11-Keto-β-Boswellic Acid | Acetyl-11-Keto-β-Boswellic Acid | γ-cyclodextrin complex | oleogum resin | 100 mol/kg (i.p.) | 50 μg LPS-injected apoE−/− mices-induced atherosclerotic model | Anti-inflammatory anti-atherogenic | MCP-1, MCP-3, IL-1α, MIP-2, VEGF, TF ↓ | IKK, p-IκBα, p65↓, IκBα↑ | NF-κB signaling | [135] |
10 μmol/L | 100 ng/ml LPS + human macrophages / mouse mononuclear and macrophages-induced inflammation model | |||||||||
Ginsenoside Re | Ginsenoside Re | - | Ginseng | 10 µM | 50 ng/ml LPS + peritoneal macrophages to induce inflammation model | anti-inflammatory | IL-1β, TNF-α, COX-2, iNOS, IRAK-4, IRAK-1↓ | p-IKKβ, p65, p-p65, TLR4, MyD88 ↓, IκBα ↑ | - | [137] |
Corosolic acid | Corosolic acid | Pentacyclic triterpenoid | - | 50 μM | 1 μg/ml LPS + RAW 264.7 macrophage cells -induced inflammation model | anti-inflammatory | IFN-γ ↓ | Akt, NF-κB, c-JUN, IKKα, p-IKKα, p-IKKβ ↓ | Akt/IKK/NF-κB | [139] |
Ursolic acid | Ursolic acid | 100 μM | ||||||||
Pipernigramides | compounds 42/43/44 | amide alkaloids | Piper nigrum L | 2, 4, 8 μM | 1 μg/ml LPS + RAW 264.7 macrophage cells -induced inflammation model | anti-inflammatory | IL-1β, IL-6, TNF-α, PGE2, iNOS, COX-1, COX-2 ↓ | IKKα/β, P-IKKα/β, p-IκBα, p65, p-p65 ↓, IκBα ↑ | NF-κB signaling | [141] |
Synthetic drugs | ||||||||||
Sulforaphane | Sulforaphane | isothiocyanate | Isothiocyanate, broccoli | 0.25 mg/kg/day (p.o.) | A high cholesterol die (1% cholesterol-enriched chow) for 4 weeks + new zealand white rabbits to induce atherosclerosis model | anti-oxidant stress | MDA, SOD ↓, GSH ↑ | p65 | - | [143] |
2.5, 5 μM | 5 ng/ml TNF-α + Human endothelial cells ECV-304-induced inflammation | anti-inflammatory | IL-1β, IL-6, IL-8, ICAM-1, VCAM-1, E-select ↓ | p65, p-IκBα, p-IKKβ, IKKβ, p-RhoA, RhoA, p-ROCK, ROCK↓, IκBα↓ | RhoA/ROCK/NF-κB | [146] | ||||
10 μmol/L | 4 ng/mL TNF-α + HUVECs to induce inflammation model | anti-inflammatory | EL ↓ | p50, p65, p-IKK1/IKK1, p-IKK2/IKK2, p-IκB/IκB↓, IκBα ↑ | NF-κB/EL | [91] | ||||
Vitamin C | Vitamin C | Vitamin | 10, 20, 40 mM | 10 ng/ml IL-1/100 ng/ml PMA / 0.2 mM H2O2 / 10 ng/ml TNF / 200 U/ml IFN-γ + ECV304 / HUVECs-induced inflammation model | anti-inflammatory anti-oxidant stress | IL-8 ↓ | p65, p-IκBα, IKKα, IKKβ ↓, IκBα ↑ | - | [149] | |
Zinc | Zinc | - | - | 1, 15 μM | 10 μg/ml LPS + HUVECs-induced inflammation model | anti-inflammatory | TNF-α, IL-1β, MCP-1, NO, VCAM-1 ↓ | IKKα, p65↓ | IKKα/NF-κB | [152] |
1-Deoxynojirimycin | 1-Deoxynojirimycin | Polyhydroxy alkaloid | Mulberry Leaves | 10 mg/d (p.o.) | A total of 144 patients with stable angina pectoris and blood stasis syndrome | anti-oxidant anti-inflammatory | hs-CRP, IL-6, TNF-α, SOD, MDA ↓ | IKK, p65↓, IκBα ↑ | - | [153] |
Ebselen | 2-phenyl-1,2-benzisoselenazol-3[2H]-one] | organoselen-ium compound | Synthetic compound | 20 mg/kg/d | C57Bl/J6 apoE−/− mice + streptozotocin-induced diabetic apoE−/− mouse model | anti-atherosclerosis | VEGF, RAGE, NOX2, SOD-1, GPx1, catalase, TNF-α ↓ | p-IKK, p-JNK↓ | - | [42] |
0.03 μmol/L | 100 μmol/L H2O2 + HAECs-induced inflammation model | |||||||||
Polyethylene glycol-superoxide dismutase | - | superoxide anion scavenger | - | 300 U/mL | 100 μmol/L homocysteine + HUVECs / HAECs to induce endothelial injury | anti-oxidant stress, anti-inflammatory | SOD ↓ | p-IκBα, IKKα, IKKβ, p65↓, IκBα ↑ | - | [156] |
Prostaglandin A1 | - | - | 30 μmol/L | |||||||
FABP 4/5 inhibitors | Compound A16/B8 | FABP 4/5 inhibitor | - | 30, 60 µM | 100 ng/ml LPS + RAW 264.7 macrophage cells -induced inflammation model | anti-inflammatory | MCP-1, TNF-α, IL-6, COX-2↓ | IKK, p-IKK, p65, p-p65 ↓ | IKK/NF-κB | [181] |
BAY11-7082 analogs | 8-tosylamino quinoline | IKK inhibitor | - | 20 μmol/L | 1 μg/ml LPS + RAW264.7 macrophage cells and peritoneal macrophages-induced inflammation model | anti-inflammatory | NO, PGE2, TNF-α, IL-12p40, iNOS, COX-2 ↓ | p65, IKK, p-IKK, Akt, p-Akt, p-IκBα ↓, IκBα ↑ | Akt/NF-κB | [159] |
Losartan | Losartan | Ang II type 1 receptor antagonist | - | 30 mg/kg | male apoE−/− mice + 5/6 nephrectomy to induce experimental mild uremia | antiinflammatory anti-atherosclerosis | BUN, CRE, CCL2/MCP-1, CX3CL1, TNF-α, IL-6↓ | IRE1α, p-IRE1α, GRP78, p-IKK, IKKα, IKKβ, p65 ↓, IκBα ↑ | IRE1α/IKK/NF-κB | [70] |
10 μmol/L | 1 μg/ml Ang II + RAW264.7 murine macrophages to induce inflammation model | |||||||||
TMP195 | TMP195 | class IIa histone deacetylase inhibitor | 50 mg/kg/d, i.p | ApoE–/– mice + Western-type diet (21% fat) to induce atherosclerosis model | alleviate vascular inflammation | CXCL-1, CCL-2, TNF-α, IL-1β, IL-6, IL-8, VCAM-1 ↓ | IKKβ, p-p65 ↓ | IKKβ/NF-κB | [68] | |
3, 5 µmol/L | 50 ng/mL mouse recombinant + Human Peripheral Blood Mononuclear Cells (PBMCs) to induce inflammation model | |||||||||
LCY-2-CHO | LCY-2-CHO | carbazole analogue | - | 3, 10 μM | 50 nM TNF-α/10 ng/ml IL-1β + Rat aortic VSMCs to induce inflammation model | anti-inflammatory | HO-1, Nrf2, Lamin B, iNOS, COX-2, IL-8, GRO-α, eNOS, p-eNOS, MBP ↓ | IKK, p-IKK ↓, IκBα ↑ | IKK/NF-κB | [160] |
other drugs | ||||||||||
β-defensins 3 | β-defensins 3 | Antimicrobial peptide | mucosa and epithelial cells | 15, 10, 5 μg/ml | 40 ng/ml TNF-α + (HUVECs + TPH-1)-induced inflammation and monocyte adhesion | anti-inflammatory, reduce monocyte adhesion | IL-6, IL-8, MCP-1, MIF, ICAM-1, VCAM-1, Bax, E-selectin, ROS, cleaved caspase-3/caspase-3↓, Bcl-2 ↑ | p-IKK, p-IκBα, p-p65↓, IκBα ↑ | NF-κB, MAPK | [162] |
Glucagon-like peptide 1 | Liraglutide | incretin hormone | gut enteroendocrine cells | 30 nM | 5 ng/ml TNF-α + HUVECs-induced oxidative damage and inflammation | anti-oxidant stress, anti-inflammatory | SOD, catalase, GPx ↑ | PKC-α, P-IKKα/β, IKKα, IKKβ ↓, IκBα ↑ | - | [165] |
s.c and tail i.v 0.2 mg/kg | 2.5 mg/kg adriamycin (i.p.) + GK rats for 6 weeks- induced diabetic cardiomyopathy model | anti-oxidant stress, alleviate myocardial fibrosis | MDA↓, SOD, GPx ↑ | PPARγ↑, p65 ↓ | - | [164] | ||||
Mediterranean diet + CoQ | - | - | - | Med diet + CoQ | Clinical inclusion criteria: age 65 years or older, body mass index 20 ~ 40 kg/m2, total cholesterol concentration ≤ 8.0 mmol/L, and nonsmokers | anti-inflammatory | IL-1β, JNK-1, MMP-9, sXBP-1, CRT, BiP/Grp78 ↓ | p65, IKKβ ↓, IκBα ↑ | - | [182] |
Jianpi huazhuo tiaozhi granules | - | chinese herbal medicine | - | 2.5%, 5%, 10% concentrations | 100 mg/L ox-LDL + RAW264.7 macrophage cells- induced oxidative stress injury model | anti-oxidant stress anti-apoptosis | MDA, SOD, ROS, NOX4, p22phox ↓ | IKKα, IKKβ, p65↓ | NOX/ROS/NF-κB | [62] |
Fufang-Zhenzhu-Tiaozhi Capsule | - | Chinese herbal medicine | - | 0.66 mg/kg/d | male new zealand rabbits + balloon rubbing the endothelium of the abdominal aorta + a high fat diet (1.5% cholesterol, 0.5% sodium cholate, 8% lard, and 10% egg yolk powder)-induced atherosclerosis model | lipid-lowering anti-inflammatory | TC, TG, LDL-C, VLDL-C, IL-1, IL-6, IL-8, IL-12, TNF-α, MCP-1, ICAM-1 ↓ | p65, p-IκBα, IKK-α, p-IKKα/β↓, IκBα ↑ | IKK/NF-κB | [169] |